NCT07191977View on ClinicalTrials.gov

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Esophageal Squamour Cell Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.

DRUG

Palbociclib

Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.

All Listed Sponsors
lead

West China Hospital

OTHER